Abstract 651P
Background
XNW27011 is a novel claudin 18.2(CLDN 18.2)-targeting ADC with the TMALIN® linker, a proprietary TOP1i payload more potent than Dxd, and homogeneous DAR of 8. Here we report the preliminary results from the dose escalation phase of the first in human, multi-center, open-label, phase I/II study of XNW27011 in patients (pts) with locally advanced and/or metastatic solid tumors who have failed or are intolerant to standard therapies.
Methods
XNW27011 was given starting from 0.6 mg/kg (Q3W, IV) in an accelerated titration followed by 3+3 escalation scheme. The primary objective of dose escalation phase was to determine MTD.
Results
As of Apr. 15, 2024, 16 pts were enrolled in 6 dose cohorts from 0.6 to 6.0 mg/kg, including 11 GC/GEJC, 2 OC, 2 PC, and 1 duodenal periampullary adenocarcinoma (ECOG 0-1, majority of pts received ≥3 lines of prior therapy). 12 pts had various levels of CLDN18.2-expression (≥1%, IHC ≥ 1+). During DLT period, the most common AEs were nausea and vomiting, followed by white blood cell decrease, neutrophil decrease and anemia. No ≥ grade 3 TRAEs were observed below 4.8 mg/kg during DLT period. No ILD or MMAE-related ocular AEs and peripheral neuropathy were observed. One patient experienced DLT at 6.0 mg/kg. The table summarized efficacy in 14 evaluable pts. Efficacy was observed even at doses as low as 0.6 mg/kg. Prior PD-1 immunotherapy, irinotecan or CLDN18.2 antibody therapy seemed not to impact efficacy. Table: 651P
Efficacy outcomes
All tumor (n=14) | CLDN18.2+ * tumor (n=11) | CLDN18.2+ * GC/GEJC 1 (n=8) | CLDN18.2+ * OC 2 (n=2) | CLDN18.2+ * PC 3 (n=1) | |
ORR | 50% (7/14) | 64% (7/11) | 63% (5/8) | 50% (1/2) | 100% (1/1) |
DCR | 86% (12/14) | 100% (11/11) | 100% (8/8) | 100% (2/2) | 100% (1/1) |
*CLDN18.2+: any level of CLDN18.2 expression, defined as CLDN 18.2 _1%, IHC_1+; GC/GEJC1: gastric cancer/gastroesophageal junction cancer; OC2: ovarian cancer; PC3: pancreatic cancer
XNW27011 has shown similar concentration-time curves of ADC and TAb, long T1/2= 5-9 days, and extremely low free payload at all tested doses (Cmax of 0.253 to 1.65 ng/mL corresponding to 0.6-6.0 mg/kg doses).
Conclusions
XNW27011 demonstrated a favorable safety profile with large therapeutic window, superior preliminary efficacy across tumor type and CLDN 18.2 expression level, and excellent PK properties including low payload plasma exposure. The study is ongoing with the expansion phase being initiated in multiple tumor cohorts.
Clinical trial identification
Editorial acknowledgement
Xiujing Emma Feng from Evopoint Biosciences USA, Inc.
Legal entity responsible for the study
Evopoint Biosciences Co. Ltd.
Funding
Evopoint Biosciences Co. Ltd.
Disclosure
H. Zhao, Y. Hu, H. Wei, Y. Zhao, Y. Wang, Q. Shi, J. Li: Financial Interests, Personal, Full or part-time Employment: Evopoint Biosciences Co. Ltd.; Financial Interests, Personal, Stocks/Shares: Evopoint Biosciences Co. Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
723P - A phase II study of cadonilimab plus chemotherapy in persistent recurrent/ metastatic cervical cancer patients who failed previous immuno/chemotherapy
Presenter: Li Xiaoling Li
Session: Poster session 01
724P - Preliminary outcomes from a phase Ib/II study of the highly potent PI3K-mTOR dual inhibitor WX390 combined with toripalimab in patients with advanced cervical cancer
Presenter: Guiling Li
Session: Poster session 01
725P - Treatment of patients with metastatic or relapsed cervical cancer: Results from a quality assurance program of the AGO Study Group
Presenter: Dominik Denschlag
Session: Poster session 01
726P - Efficacy and safety of pembrolizumab plus olaparib combination therapy in recurrent cervical cancer progressed on platinum-based chemotherapy: Results from the phase II trial of GOTIC-025
Presenter: Kosei Hasegawa
Session: Poster session 01
727P - Real-world efficacy and safety of cadonilimab in recurrent or metastatic cervical cancer: A multicenter retrospective analysis in China
Presenter: Yang Sun
Session: Poster session 01
Resources:
Abstract
728P - Chemotherapy plus tislelizumab in young patients with cervical cancer preserve fertility: A phase II study
Presenter: Danbo Wang
Session: Poster session 01
729P - Patterns of survivorship care of cervical cancer patients with or without HIV infection in Botswana 2015-2022
Presenter: Sheldon Amoo-Mitchual
Session: Poster session 01
730P - Validation of circulating tumor DNA for prognostication and monitoring in metastatic endometrial carcinoma: Ancillary results from the phase II randomized GINECO trial UTOLA
Presenter: Guillaume Beinse
Session: Poster session 01
731P - Post-progression survival outcomes in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial who received follow-up immunotherapy
Presenter: Mansoor Raza Mirza
Session: Poster session 01
732P - Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as a first-line treatment for endometrial cancer (EC): Progression-free survival (PFS) by clinical factors in DUO-E
Presenter: Stephanie Blank
Session: Poster session 01